RBC Capital Markets projects a bullish outlook for the MedTech sector in 2025, driven by innovation, favorable demographics, and pro-business policies under the Trump administration. The firm anticipates a “catalyst-rich” year, spotlighting large-cap leaders like Intuitive Surgical (ISRG) and Boston Scientific (BSX) for standout performance. ISRG’s da Vinci 5 system launch and BSX’s advancements in pulsed field ablation and Watchman devices are expected to fuel double-digit sales and EPS growth.

Dislocated large-cap names such as DexCom (DXCM), Medtronic (MDT), and Edwards Lifesciences (EW) also offer recovery opportunities, with innovations like DXCM’s G7 sensor, MDT’s renal denervation (RDN), and EW’s growth in transcatheter valve therapies (TAVR). In the mid-cap space, Inspire Medical Systems (INSP) and Globus Medical (GMED) stand out, leveraging market leadership and innovation in sleep apnea and robotic-assisted surgery.

Sector-wide tailwinds include aging demographics, AI integration, and a shift to efficient care settings, while Trump-era policies supporting corporate tax reductions and innovation-friendly regulations are seen as additional growth enablers. RBC expects MedTech to maintain strong healthcare positioning, projecting multi-year growth underpinned by innovation and market expansion.

https://www.investing.com/news/stock-market-news/medtech-sector-outlook-for-2025-rbc-3779779